Skip to main content
Premium Trial:

Request an Annual Quote

Hybrigenics Receives Patent Protection for Protein Mapping Technology

NEW YORK, March 21 - Hybrigenics of Paris has received US patent protection for a key part of its protein interaction technology, a development that may force competitors using similar techniques to pay license fees or change their technology, the company said Wednesday.

Donny Strosberg, Hybrigenics' CEO, said "one or two" companies are currently employing Hybrigenic's Protein Interaction Mapping (PIM) technology, which it uses to map out protein interactions for major diseases, but declined to name the specific companies.

"Now we have recognition that our technology is the only one that's patentable, and to those who are using our technology: 'cease and desist,' as they say," said Strosberg.

Hybrigenics licenses the PIM technology from the Institut Pasteur, also in Paris. The Institut was awarded the patent February 13, and currently licenses the technology exclusively to Hybrigenics.

The US patent, entitled "Fast and exhaustive method for selecting a prey polypeptide interacting with a bait polypeptide of interest: application to the construction of maps of interactor polypeptides," covers a technique for high-throughput screening of a yeast two-hybrid system to identify protein-protein interactions in any yeast cell-type.

The method is part of PIM's fluorescent tagging technology, which employs fragments of cDNA, that encode "prey proteins," and throws carefully selected fluorescently tagged "bait" proteins at these encoded, yet unknown prey proteins. It then discovers which prey proteins stick to the bait.   

By tracing the prey protein back to its sequence, the company can characterize its domain. Using this information and bioinformatics algorithms, the company is able to identify the domains of thousands of proteins and map out large webs of protein-protein interactions. 

Hybrigenics has applied but not yet received a patent in the European Union for the technology. However, Strosberg said the US patent will apply to transfers of data over the Internet, and that in any case, most of the company's business is in the US.

Strosberg added that the patent may increase the value of his company in the eyes of investors, because the protein-mapping technology can no longer be seen as generic.

Hybrigenics has studied protein interactions in a number of pathogenic organims, such as Helicobacter pylori , as well as in yeast, drosophila, and human cells. In January, scientists at Hybrigenics published a paper in Nature describing protein interactions in Helicobacter pylori using its PIM technology.

In February, the company signed its first marketing deal for the technology, a three-year collaboration with Servier, a privately-owned French pharmaceutical company, in which Hybrigenics will map protein interactions associated with cancer. 

Strosberg has said the company is currently looking for opportunities to expand its business into the US, through acquisition of a US company or the opening of a US facility.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.